BMO raises AbbVie target price to $340 from $300
ABBV•BMO raised its target price for AbbVie to $340 from $300.
Related News
Seer shareholders demand valuation disclosure after board rejects buyout offers
SEER•
Actuate Therapeutics receives US patent allowance for elraglusib oral tablets
ACTU•
CrowdStrike partners with Dynatrace to integrate cybersecurity and observability platforms
CRWD•
Nasdaq trade halt continues, reason not available at 8:05 a.m.
UCFIW•
Axcelis, Veeco now expect merger to close by end of Q1 2027
VECO•